News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Palisade Bio, Inc. (NASDAQ:PALI) has received a consensus "Buy" recommendation from brokerages, with an average one-year target price of $9.00. The article details recent analyst ratings, including several "buy" and "strong-buy" recommendations, alongside some changes to "hold" and "sell" ratings. It also highlights recent …
Soleus Capital Master Fund, L.P. and its affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 13,063,687 shares of Palisade Bio, Inc. (PALI) common stock. This represents a 7.5% stake in the company, based on 174,270,558 shares outstanding as …
Oppenheimer analyst Leland Gershell reiterated a Buy rating on Palisade Bio (PALI) with an $8.00 price target. The company currently holds a Strong Buy consensus rating with an average price target of $7.00. Despite reporting a wider GAAP net loss in its latest quarter, …
(RTTNews) - Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss and provided a business update. Company Profile Palisade Bio develops prodrugs for patients living with inflammatory and fibrotic …
Palisade Bio (NASDAQ:PALI) announced plans to initiate a Phase 2 clinical trial for its drug candidate PALI-2108 in ulcerative colitis during the second half of 2026, with results expected in late 2027. The company also intends to file an investigational new drug application for …
Palisade Bio (NASDAQ:PALI) announced its quarterly earnings, reporting a loss of $0.05 per share, which met analyst expectations, and revenue of $0.50 million. The stock saw a slight dip, trading down 0.5% to $2.10, while analysts maintain an overall "Buy" rating with a target …
Palisade Bio (NASDAQ: PALI) reported a Q2 2026 net loss of $10.6 million, significantly wider than the $2.8 million loss in Q2 2025, primarily due to increased R&D expenses for its lead candidate, PALI-2108. Despite the widening loss, the company's EPS of $(0.05) met …
PALISADE BIO, INC. (PALI) reported second-quarter 2026 financial results with $0.5 million in revenue and a net loss of $10.6 million, or $(0.05) diluted EPS. This marks an increase in revenue compared to the year-ago quarter, though the net loss widened. The company also …
Palisade Bio reported Q2 2026 financial results, including a net loss of $10.6 million, and provided an update on its lead Inflammatory Bowel Disease (IBD) candidate, PALI-2108. The company plans to initiate Phase 2 ASCENTRA-UC trials for ulcerative colitis in the second half of …
Palisade Bio, Inc. reported its second-quarter 2026 financial results, highlighting the continued advancement of PALI-2108 into Phase 2 development for inflammatory bowel disease (IBD). The company expects to begin enrollment for the Phase 2 ASCENTRA-UC trial in the second half of 2026, with primary …
Renaissance Technologies LLC decreased its stake in Palisade Bio, Inc. by 39% in the first quarter, selling 928,100 shares but still owning 1.45 million shares valued at approximately $2.55 million. Despite this, institutional investors collectively hold 11.79% of PALI, and analysts maintain a consensus …
John David Finley, CEO and CFO of Palisade Bio (NASDAQ:PALI), sold 146,798 shares for approximately $303,343 to cover tax obligations following the vesting of restricted stock units. This transaction occurred after a significant 184% return over the past year, though InvestingPro data suggests the …
This article provides an earnings forecast for Palisade Bio Inc (PALI), highlighting its current earnings forecast score of 8.80 and an average price target of $8.00 based on 10 analyst ratings. Most analysts recommend a "Buy" for PALI, with expected EPS for the next …
Palisade Bio (PALI) is anticipated to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts forecasting a loss of $0.05 per share. The company's stock opened at $1.90, near its 50-day and 200-day moving averages, and has seen insider …
BlackRock, Inc. has reported a 6.0% beneficial ownership in Palisade Bio, Inc. common stock as of June 30, 2026, through a Schedule 13G filing. This amounts to 10,436,760 shares, representing holdings where BlackRock maintains sole voting power over 10,326,107 shares and sole dispositive power …
Oppenheimer initiated coverage on Palisade Bio Inc. with a Buy rating and a $8 price forecast, highlighting the company's lead drug candidate, PALI-2108, for inflammatory bowel disease (IBD). This oral PDE4 inhibitor prodrug, designed for targeted delivery to the ileum and colon, is advancing …
This article provides a valuation analysis for Palisade Bio Inc (PALI), stating its current valuation score is 9.13, ranking 54th in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 16.64, which is 13.78% below its recent high and 155.82% above …
This article provides an overview of Palisade Bio Inc (PALI)'s dividend and stock split history. It notes that the company has distributed no dividends in the past five years and details several merger-related stock splits that have occurred between 2021 and 2024. The stock …
This article provides a risk assessment for Palisade Bio Inc (PALI), noting its current score of 2.82, ranking it 183 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's beta of 1.53, indicating higher volatility compared to the S&P …
The article discusses the revenue breakdown for Palisade Bio Inc (PALI), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information, including its market cap and P/E ratio, but …
This article provides a comprehensive stock analysis of Palisade Bio Inc (PALI) by TradingKey, assigning it a solid score reflecting healthy fundamentals and high growth potential. The company's valuation is deemed fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership …
Palisade Bio Inc (PALI) currently trades at $1.950, reflecting a 3.47% daily decrease. Despite recent stock performance, the company exhibits strong fundamentals, including high growth potential and a "Buy" rating from analysts with a target price of $10.40. Palisade Bio is a clinical-stage biopharmaceutical …
Palisade Bio Inc (PALI) currently trades at $1.950, reflecting a 3.47% daily decrease. Despite recent stock performance, the company exhibits strong fundamentals, including high growth potential and a "Buy" rating from analysts with a target price of $10.40. Palisade Bio is a clinical-stage biopharmaceutical …
Oppenheimer initiated coverage on Palisade Bio (NASDAQ: PALI) with a Buy rating, highlighting its potential in the inflammatory bowel disease market. The company's lead drug, PALI-2108, a once-daily oral PDE4 inhibitor, is seen as a strong candidate for ulcerative colitis and Crohn's disease due …
Oppenheimer initiated coverage of Palisade Bio (PALI) with an outperform rating and an $8 price target, representing a 321% upside. This initiation caused the stock to jump approximately 14% in morning trading. Analyst Leland Gershell views strong potential in the company's PALI-2108.
Oppenheimer has initiated coverage on Palisade Bio (PALI) with an 'Outperform' rating and a price target of $8.00, suggesting significant upside from its current price of $1.90. Despite a low GF Score™ of 35/100 due to profitability challenges typical for a clinical-stage biotech, the …
Search by ticker symbol or company name and select a result to open its chart.